

Irina Kopylova, Elizaveta Orlova, Irina Yarovaya, Maria Kareva, Valentina Peterkova

Endocrinology Research Centre, Institute of Pediatric Endocrinology, Moscow, Russia

The authors declare that there are no conflicts of interests associated with this manuscript

BACKGROUND

Congenital lipid adrenal hyperplasia (CLAH) is the most severe form of congenital adrenal hyperplasia, characterized by lack of synthesis of all kinds of steroids in adrenals and gonads due to defects in gene of Steroidogenic Acute Regulatory protein (StAR). 46,XX patients can have a spontaneous puberty due to residual estrogen synthesis by a StAR-independent pathway in ovary. Development of ovarian cysts may be derived from persistent anovulation and impairment of ovarian StAR-independent steroidogenesis by lipid deposition.

CASE REPORT

We report a 13-years-old 46,XX patient with CLAH, which presented a spontaneous puberty and enlarged polycystic ovaries. A congenital adrenal insufficiency was diagnosed due to hyponatremia, hyperkalemia and hyperpigmentation at 3 weeks after birth. She was successfully treated with hydrocortisone and fludrocortisone. The decreased level of all steroid hormones was determined by multisteroid analysis. Two heterozygous mutations (466delG and W245X) were detected in the StAR gene. Breast development was observed at the age of 11. It progressed to the Tanner stage 4 by 13,5 years old, but no pubic and axillary hair was observed. At the age of 13 giant cyst in the right ovary (200 cm³) was revealed by ultrasound, which was successfully treated with cyclic progesterone therapy. Estrogen therapy was not prescribed because of normal gonadotropins and estradiol levels (Tab.1). After 5-month of treatment with progesterone the increase of LH level (20.9 U/l) was detected and enlarged polycystic ovaries was revealed by MRI (right ovary 38×35×38 mm; left ovary 35×28×36 mm). The combined therapy with estrogen and progesterone was started.

Table 1. Clinical and laboratory data of female patient with congenital lipid adrenal hyperplasia (CLAH)

Age	Tanner stage	LH, U/l	FSH, U/l	Estradiol, pmol/l	Ovaries, cm ³	Progesterone or estrogen treatment
11. y	Brest 2 Pubis 1	0,2 (1,5-4,1)	5,3 (1,0-10,8)	45 (35-90)	Ovarian cyst 1,8 cm	
12 y	Brest 3 Pubis 1	0,6 (2,0-6,3)	3,2 (1,5-12,8)	40 (50-220)	Ovaries volume 4,5 cm ³	
13 y	Brest 3 Pubis 1	5,89 (2,0-6,3)	4,16 (1,5-12,8)	221,9 (50-220)	Ovarian cyst 200 cm ³	Cyclic Progesterone therapy
13,5 y	Brest 4 Pubis 1	20,9 (3,2-9,8)	10,1 (1,5-11,7)	101,7 (80-330)	Polycystic ovaries 21,6 cm ³ and 26,2 cm ³	Combined therapy with Estrogen+Progesterone

CONCLUSIONS

Ovarian cysts can be seen in 46,XX CLAH patients at puberty. Replacement therapy with estrogen and progesterone can prevent the ovarian cysts formation. The long-term follow-up is necessary in female patients with CLAH.

